Any thoughts on who might be interested in partnering with AVI?
Based on the recent stock action, you could guess that CG can't get any partners to pony up some cash and do a deal before the 48 week data is out so he has to go raise some money via a secondary. If that's true, its certainly a negative short term. And it would be rolling the dice big time that the 48 week data will be robust.
I know many big pharm's got out of RNAi technology in the last year or so. Maybe they realized that, while there is promise in the technology, it will be expensive and time consuming to develop all the drugs. Maybe they figured it would be better to just let the small biotech's do the work and then partner with them once there is a promising drug. I guess I'm hoping that is what's going on. Either that or they spent a lot of money on RNAi and figured out that the technology won't lead to drugs that will provide a clinical benefit.
Would it make sense for GSK to partner with AVI? By doing so, they would lock down exon skipping, avoid spending money on future patent litigation, and leverage the existing spending they are doing with Prosena.
Any thoughts on who else might be interested? Pfizer? Celgene?